Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

(1995): Cortes JE+, J Clin Oncol 13, 2643
Mucosal
Mucositis
(2003): Suzuki M+, Jpn J Clin Oncol 33(6), 297
(2002): Marx G+, Br J Cancer 87(8), 846 (with ifosfamide)
(2002): Rein DT+, Gynecol Oncol 87(1), 98 (with carboplatin)
Stomatitis (5–42%)
(2007): Tashiro H+, Gan To Kagaku Ryoho 34(3), 393 (with
cyclophosphamide) (25%)
(2006): Izquierdo MA+, Eur J Cancer 42(12), 1789 (with
paclitaxel)
(2005): G Oumlker E+, Neth J Med 63(9), 364
(2003): Han JY+, Cancer 98(9), 1918 (33%) (with capecitabine)
(2003): Qin YK+, Ai Zheng 22(4), 415
(2002): Bonneterre J+, Br J Cancer 87(11), 1210 (5%)
(2002): Eich D+, Am J Clin Oncol 25(6), 599 (passim)
(1996): Edmonson JH+, Am J Clin Oncon 19, 574
Hair
Hair – alopecia (80%)
(2007): Tashiro H+, Gan To Kagaku Ryoho 34(3), 393 (with
cyclophosphamide) (100%)
(2007): Tashiro H+, Gan To Kagaku Ryoho 34(3), 453 (100%)
(2004): Gridelli C+, Br J Cancer 91(12), 1996
(2003): Qin YK+, Ai Zheng 22(4), 415
(2003): Yoshida K+, Gan To Kagaku Ryoho. 30(12), 1927
(2002): Eich D+, Am J Clin Oncol 25(6), 599 (passim)
(2002): Koukourakis MI+, Anticancer Res 22(4), 2491
(2002): Rein DT+, Gynecol Oncol 87(1), 98 (with carboplatin)
(1995): Lemenager M+, Lancet 346, 371
Nails
Nails – Beau’s lines (transverse nail bands)
(2001): Camidge DR+, Lancet Oncol 2(6), 342
(1999): Correia O+, Dermatology 198, 288
Nails – changes (sic)
(2003): Kuroi K+, Breast Cancer 10(1), 10
(2003): Rafi L+, Eur J Dermatol 13(6), 610 (severe)
(2003): Yoshida K+, Gan To Kagaku Ryoho. 30(12), 1927
(2002): Pavithran K+, Br J Dermatol 146(4), 709
(2001): Kuroi K+, Gan To Kagaku Ryoho (Japanese) 28(6), 797
(2001): Wasner G+, Lancet 357(9260), 910
Nails – discoloration
(2003): Mourad YA+, Dermatol Online J 9(3), 15
(2002): Nicolopoulos J+, Australas J Dermatol 43(4), 293
Nails – dystrophy
(2006): Alexandrescu DT+, Int J Dermatol 45(11), 1334 (with
Trastuzumab)
Nails – hyponychial dermatitis
(2003): Chen GY+, Br J Dermatol 148, 1071 (with capecitabine)
Nails – loss
(2004): Mackey JR+, Clin Breast Cancer 5(4), 287 (45%) (with
capecitabine)
(2003): Maisano R+, Anticancer Res 23(2C), 1923
(2003): Mourad YA+, Dermatol Online J 9(3), 15
Nails – onycholysis
(2003): Mourad YA+, Dermatol Online J 9(3), 15
(2002): Eich D+, Am J Clin Oncol 25(6), 599 (passim)
(2002): Nicolopoulos J+, Australas J Dermatol 43(4), 293
(1999): Correia O+, Dermatology 198, 288
(1998): Obermair A+, Ann Oncol 9, 230
(1996): Dreyfuss AL+, J Clin Oncol 14, 1672
(1996): Trudeau ME, Semin Oncol 22, 17
(1995): Zimmerman GC+, Arch Dermatol 131, 202
Nails – paronychia
(2002): Nicolopoulos J+, Australas J Dermatol 43(4), 293
(1999): Correia O+, Dermatology 198, 288 (painful)
Nails – pigmentation
(2002): Eich D+, Am J Clin Oncol 25(6), 599 (passim)
DOCETAXEL 187
(1999): Correia O+, Dermatology 198, 288 (orange
discoloration)
(1998): Jacob CI+, Arch Dermatol 134, 1167 (nail bed
dyschromia)
Nails – subungual abscess
(2002): Nicolopoulos J+, Australas J Dermatol 43(4), 293
(2000): Vanhooteghem O+, Br J Dermatol 143, 462
Nails – subungual hemorrhages
(2002): Nicolopoulos J+, Australas J Dermatol 43(4), 293
(1999): Correia O+, Dermatology 198, 288
Nails – subungual hyperkeratosis
(1999): Correia O+, Dermatology 198, 288
Nails – transverse superficial loss of nail plate
(1999): Correia O+, Dermatology 198, 288
(1997): Llombart-Cussac A+, Arch Dermatol 133, 1466
Eyes
Epiphora
(2007): Tinker AV+, Gynecol Oncol 104(3), 647 (8%)
(2006): Esmaeli B+, J Clin Oncol 24(22), 3619 (64%)
(2006): Kintzel PE+, Pharmacotherapy 26(6), 853
(2006): Tsalic M+, Med Oncol 23(1), 57 (33%)
(2005): Esmaeli B, Clin Breast Cancer 5(6), 455
(2003): Kuroi K+, Breast Cancer 10(1), 10
(2003): Maisano R+, Anticancer Res 23(2C), 1923
Other
Abdominal pain
(2003): Viret F+, Pancreas 27(3), 214
Anaphylactoid reactions/Anaphylaxis
(2007): Gunthert AR+, Gynecol Oncol 104(1), 86
Application-site fixed eruption
(1995): Zimmerman GC+, Arch Dermatol 131, 202
Cough
(2004): Gridelli C+, Br J Cancer 91(12), 1996
Death
(2006): Laber DA+, Am J Clin Oncol 29(4), 389 (4%)
(2003): Han JY+, Cancer 98(9), 1918 (2 cases) (with
capecitabine)
(2002): Morris MJ+, Urology 60(6), 1111
Extravasation
(2005): Barcelo R+, Arch Dermatol 141(10), 1326
Fever
(2006): Yip AY+, Breast Cancer 13(2), 192 (19%)
Fibrosis
(2000): Cleveland MG+, Cancer 88, 1078 (generalized)
Hypersensitivity (1–28%)
(2005): Feldweg AM+, Gynecol Oncol 96(3), 824
(2004): Furugen Y+, Gan To Kagaku Ryoho 31(8), 1205 (25%)
(with carboplatin)
(2002): Denman JP+, J Clin Oncol 20(11), 2760 (previous
hypersensitivity to paclitaxel)
(2002): Eich D+, Am J Clin Oncol 25(6), 599 (passim)
(1996): Hudis CA+, J Clin Oncol 14, 58
(1995): Bedikian AY+, J Clin OncoI 13, 2895
(1993): Schrijvers D+, Ann Oncol 4, 610 (28%)
Inappropriate secretion of antidiuretic hormone (SIADH)
(2000): Langer-Nitsche C+, Acta Oncol 39(8), 1001
Infections
(2002): Bonneterre J+, Br J Cancer 87(11), 1210 (2%)
(2002): Koukourakis MI+, Anticancer Res 22(4), 2491
(2002): Souglakos J+, Cancer 95(6), 1326 (11.7%)
Injection-site dermatitis
(2002): Hirai K+, Gynecol Obstet Invest 53(2), 118
Injection-site erythema
(2002): Hirai K+, Gynecol Obstet Invest 53(2), 118
(1995): Zimmerman GC+, Arch Dermatol 131, 202
Injection-site exanthems
(2002): Hirai K+, Gynecol Obstet Invest 53(2), 118